Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial

Thomas Walter, Astrid Lièvre, Romain Coriat, David Malka, Farid El-Hajbi, Frédéric Di Fiore, Olivia Hentic, Denis Smith, Vincent Hautefeuille, Guillaume Roquin, Marine Perrier, Laëtitia Dahan, Victoire Granger, Iradj Sobhani, Laurent Mineur, Patricia Niccoli, Eric Assénat, Jean‐Yves Scoazec, Karine Le Malicot, Côme Lepage, Catherine Lombard‐Bohas